About
Chronic urinary system diseases, including bladder cancer, kidney cancer, prostate cancer, stones, renal cysts, and benign prostatic hyperplasia, are a significant global public health challenge. These conditions severely affect patients' quality of life and burden healthcare systems. Despite existing preventive and therapeutic measures, their incidence and mortality rates continue to rise. A deeper understanding of their pathogenesis and risk factors is crucial for developing more effective prevention and treatment strategies.
This study will use UK Biobank data to explore risk factors for urinary system diseases, including demographic characteristics, lifestyle, environmental factors, biochemical markers, plasma metabolites, imaging data, and genetic susceptibility. We aim to identify potential biomarkers for early screening and precise interventions. Mendelian randomization will assess causal relationships between risk factors and disease. We will integrate plasma proteomics, metabolomics, and genomics data to investigate biological functions and regulatory mechanisms. Artificial intelligence and machine learning will be used to develop predictive models, combining demographic, dietary, biological sample, proteomic, and genomic data.
The study will identify new risk factors for urinary system diseases and provide scientific evidence to inform public health policies and clinical practices. This will facilitate the development of more effective prevention and treatment strategies, ultimately improving patient outcomes and quality of life. By leveraging UK Biobank data and employing advanced analytical techniques, we anticipate making significant contributions to the understanding and management of these conditions.